+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Service, Customer Type, Therapeutic Area, Region, with Growth Forecasts, 2025-2030- Product Image
U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Service, Customer Type, Therapeutic Area, Region, with Growth Forecasts, 2025-2030- Product Image
New

U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Service, Customer Type, Therapeutic Area, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • April 2025
  • Region: United States
  • Grand View Research
  • ID: 5983063
Description Jump to:
The U.S. Small Molecule Innovator API CDMO Market was valued at USD 8.80 Billion in 2024, and is projected to reach USD 12.60 Billion by 2030, rising at a CAGR of 6.00%. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited’s Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights

  • Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
  • Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
  • Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
  • West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Information Analysis
1.4.2. Market Formulation & Data Visualization
1.4.3. Data Validation & Publishing
1.5. Model Details
1.5.1. Commodity Flow Analysis (Model 1)
1.5.2. Top Down Market Estimation (Model 2)
1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
1.5.4. Multivariate Analysis (Model 4)
1.6. List of Secondary Sources
1.7. List of Abbreviations
1.8. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Investments & Funding Perspective
3.5. Clinical Trials Volume Analysis, (2024)
3.5.1. Total Number of Clinical Trials, by Phase (2024)
3.5.2. Total Number of Clinical Trials, by Study Design (2024)
3.5.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
3.6. Technology Landscape
3.6.1. Integration of AI in Small Molecule Innovator API CDMO Market
3.7. Pricing Model Analysis
3.8. Regulatory Framework
3.9. Industry Analysis Tools
3.9.1. Porter’s Five Forces Analysis
3.9.2. PESTEL by SWOT Analysis
3.9.3. COVID-19 Impact Analysis
Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Small Molecule Innovator API CDMO Market; Stage Type Movement Analysis
4.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.4. Preclinical
4.4.1. Preclinical market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Clinical
4.5.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Phase I
4.5.2.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Phase II
4.5.3.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
4.5.4. Phase III
4.5.4.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Commercial
4.6.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Small Molecule Innovator API CDMO Market; Service Movement Analysis
5.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
5.4. Process Development
5.4.1. Process development market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Preclinical development
5.4.2.1. Preclinical development market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Clinical development
5.4.3.1. Clinical development market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Scale-up optimization
5.4.4.1. Scale-up optimization market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Contract Manufacturing
5.5.1. Contract manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Clinical
5.5.2.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Commercial
5.5.3.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Analytical Testing and Quality Control
5.6.1. Analytical testing and quality control market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Packaging and Supply Chain Solutions
5.7.1. Packaging and supply chain solutions market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. Small Molecule Innovator API CDMO Market; Customer Type Movement Analysis
6.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
6.4. Pharmaceutical
6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Small
6.4.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Medium
6.4.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Large
6.4.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Biotechnology
6.5.1. Biotechnology market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Small
6.5.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Medium
6.5.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Large
6.5.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. U.S. Small Molecule Innovator API CDMO Market; Therapeutic Area Movement Analysis
7.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
7.4. Cardiovascular Diseases
7.4.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Oncology
7.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Respiratory Disorders
7.6.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Neurology
7.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Metabolic Disorders
7.8.1. Metabolic disorders market estimates and forecasts 2018 to 2030 (USD Million)
7.9. Infectious Diseases
7.9.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
7.10. Others
7.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis
8.1. Regional Dashboard
8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
8.3. Northeast
8.3.1. Competitive scenario
8.3.2. Northeast small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.3.3. New Jersey
8.3.3.1. Competitive scenario
8.3.3.2. New Jersey small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.3.4. New York
8.3.4.1. Competitive scenario
8.3.4.2. New York small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.3.5. Massachusetts
8.3.5.1. Competitive scenario
8.3.5.2. Massachusetts small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.4. Midwest
8.4.1. Competitive scenario
8.4.2. Midwest small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.4.3. Illinois
8.4.3.1. Competitive scenario
8.4.3.2. Illinois small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.4.4. Missouri
8.4.4.1. Competitive scenario
8.4.4.2. Missouri small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.4.5. North Carolina
8.4.5.1. Competitive scenario
8.4.5.2. North Carolina small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.5. West Group
8.5.1. Competitive scenario
8.5.2. West Group small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.5.3. California
8.5.3.1. Competitive scenario
8.5.3.2. California small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.5.4. Washington
8.5.4.1. Competitive scenario
8.5.4.2. Washington small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.6. South
8.6.1. Competitive scenario
8.6.2. South small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.6.3. Texas
8.6.3.1. Competitive scenario
8.6.3.2. Texas small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.6.4. Florida
8.6.4.1. Competitive scenario
8.6.4.2. Florida small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
8.6.5. Georgia
8.6.5.1. Competitive scenario
8.6.5.2. Georgia small Molecule Innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company Categorization
9.2. Company Market Position Analysis, 2024
9.3. Company Profiles
9.3.1. Lonza Group Ltd.
9.3.1.1. Company overview
9.3.1.2. Financial performance
9.3.1.3. Service benchmarking
9.3.1.4. Strategic initiatives
9.3.2. Novo Holdings (Catalent, Inc.)
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Service benchmarking
9.3.2.4. Strategic initiatives
9.3.3. Thermo Fisher Scientific, Inc.
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Service benchmarking
9.3.3.4. Strategic initiatives
9.3.4. Siegfried Holding AG
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Service benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Recipharm AB
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Service benchmarking
9.3.5.4. Strategic initiatives
9.3.6. CordenPharma International
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Service benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Samsung Biologics
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Service benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Labcorp
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Service benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Ajinomoto Bio-Pharma Services
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Service benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Piramal Pharma Solutions
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Service benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Service benchmarking
9.3.11.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 4 U.S. small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 5 U.S. small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 6 U.S. small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 7 U.S. small molecule innovator API CDMO market estimates and forecasts, by region, 2018-2030 (USD Million)
Table 8 Northeast small molecule innovator API CDMO market estimates and forecasts, by states, 2018-2030 (USD Million)
Table 9 Northeast small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 10 Northeast small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 11 Northeast small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 12 Northeast small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 13 New Jersey small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 14 New Jersey small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 15 New Jersey small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 16 New Jersey small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 17 New York small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 18 New York small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 19 New York small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 20 New York small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 21 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 22 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 23 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 24 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 25 Midwest small molecule innovator API CDMO market estimates and forecasts, by states, 2018-2030 (USD Million)
Table 26 Midwest small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 27 Midwest small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 28 Midwest small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 29 Midwest small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 30 Missouri small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 31 Missouri small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 32 Missouri small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 33 Missouri small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 34 North Carolina small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 35 North Carolina small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 36 North Carolina small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 37 North Carolina small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 38 West Group small molecule innovator API CDMO market estimates and forecasts, by states, 2018-2030 (USD Million)
Table 39 West Group small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 40 West Group small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 41 West Group small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 42 West Group small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 43 California small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 44 California small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 45 California small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 46 California small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 47 Washington small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 48 Washington small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 49 Washington small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 50 Washington small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 51 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018-2030 (USD Million)
Table 52 South small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 53 South small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 54 South small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 55 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018-2030 (USD Million)
Table 56 Texas small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 57 Texas small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 58 Texas small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 59 Texas small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 60 Florida small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 61 Florida small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 62 Florida small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 63 Florida small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
Table 64 Georgia small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018-2030 (USD Million)
Table 65 Georgia small molecule innovator API CDMO market estimates and forecasts, by service, 2018-2030 (USD Million)
Table 66 Georgia small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018-2030 (USD Million)
Table 67 Georgia small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018-2030 (USD Million)
List of Figures
Figure 1 Information procurement
Figure 2 Primary research pattern
Figure 3 Market research approaches
Figure 4 Value chain-based sizing & forecasting
Figure 5 Market formulation & validation
Figure 6 small molecule innovator API CDMO market, Segmentation
Figure 7 Market driver analysis
Figure 8 Market restraint relevance analysis
Figure 9 Porter’s five forces analysis
Figure 10 PESTEL by SWOT analysis
Figure 11 Regional marketplace: Key takeaways
Figure 12 U.S. preclinical market estimates and forecasts, 2018-2030 (USD Million)
Figure 13 U.S. clinical market estimates and forecasts, 2018-2030 (USD Million)
Figure 14 U.S. Phase I market estimates and forecasts, 2018-2030 (USD Million)
Figure 15 U.S. Phase II market estimates and forecasts, 2018-2030 (USD Million)
Figure 16 U.S. Phase III market estimates and forecasts, 2018-2030 (USD Million)
Figure 17 U.S. commercial market estimates and forecasts, 2018-2030 (USD Million)
Figure 18 U.S. process development market estimates and forecasts, 2018-2030 (USD Million)
Figure 19 U.S. preclinical development market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 U.S. clinical development market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 U.S. scale-up optimization market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 U.S. contract manufacturing market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 U.S. clinical market estimates and forecasts, 2018-2030 (USD Million)
Figure 24 U.S. commercial market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 U.S. analytical testing and quality control market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 U.S. packaging and supply chain solutions market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 U.S. others market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 U.S. pharmaceutical market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 U.S. small pharmaceutical market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 U.S. medium pharmaceutical market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 U.S. large pharmaceutical market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 U.S. biotechnology market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 U.S. small biotechnology market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 U.S. medium biotechnology market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 U.S. large biotechnology market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 U.S. cardiovascular diseases market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 U.S. oncology market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 U.S. respiratory disorders market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 U.S. neurology market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 U.S. metabolic disorders market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 U.S. infectious diseases market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 U.S. others market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Regional Outlook, 2024 & 2030
Figure 44 Northeast small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 New York small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Massachusetts small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Midwest small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 North Carolina small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 West Group small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 California small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Washington small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 South small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 Texas small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Florida small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Georgia small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

The companies profiled in this U.S. Small Molecule Innovator API CDMO market report include:
  • Lonza
  • Novo Holdings (Catalent, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences (Jubilant Biosys Limited)

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.8 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.6 Billion
Compound Annual Growth Rate6.0%
Regions CoveredUnited States
No. of Companies Mentioned12

Related Topics

Related Reports

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Small Molecule Innovator CDMO Market Report 2025 - Product Image

Small Molecule Innovator CDMO Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Small Molecule Innovator CDMO Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Small Molecule Innovator CDMO Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Small Molecule Innovator CDMO - Global Strategic Business Report - Product Image

Small Molecule Innovator CDMO - Global Strategic Business Report

  • Report
  • 66 Pages
  • Global
From
Small Molecule CDMO - Global Strategic Business Report - Product Image

Small Molecule CDMO - Global Strategic Business Report

  • Report
  • 72 Pages
  • Global
From

About the Small Molecule Innovator API CDMO Market

In the pharmaceutical industry, the Small Molecule Innovator Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market encompasses a network of companies that provide a wide array of services for the development, manufacturing, and commercialization of small molecule APIs. Small molecules, traditionally the cornerstone of pharmaceutical offerings, are organic compounds with low molecular weight that can easily enter cells and alter biological processes. The Small Molecule API CDMOs offer expertise in chemistry, helping innovator companies to accelerate the drug development pipeline from initial conception through clinical trials to market launch. These services are pivotal for pharmaceutical companies that lack the requisite infrastructure or choose to outsource these functions to focus on core competencies such as drug discovery and marketing. The CDMO market is characterized by its versatile array of technologies, including custom synthesis, process optimization, scale-up, and regulatory compliance designed to meet the bespoke needs of innovator companies. Several prominent companies are operating within the Small Molecule Innovator API CDMO market, including Catalent, Lonza Group, Patheon (part of Thermo Fisher Scientific), Siegfried Holding AG, Cambrex Corporation, Wuxi AppTec, and Piramal Pharma Solutions. These organizations have established reputations for their technical capabilities, compliance track records, and supply chain reliability, making them vital partners in the pharmaceutical manufacturing landscape. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.